Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
PSA decline
Description:
A decrease in prostate-specific antigen levels during or after prostate cancer treatment, used to assess response and prognosis.
Primary topic:
Prostate Cancer Treatment and Research (56%)
Related topics:
Prostate Cancer Treatment and Research (56%),
Prostate Cancer Diagnosis and Treatment (29%)
OpenAlex ID:
keywords/psa-decline
Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
1999
·
Glenn J. Bubley
, Michael Carducci
, et al.
·
Journal of Clinical Oncology
·
996
Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome
1993
·
Wm. Kevin Kelly
, Howard I. Scher
·
The Journal of Urology
·
364
Evaluation of Prostate-Specific Antigen Declines for Surrogacy in Patients Treated on SWOG 99-16
2006
·
Daniel P. Petrylak
, Donna Pauler Ankerst
, et al.
·
JNCI Journal of the National Cancer Institute
·
284
Prostate-Specific Antigen and Pain Surrogacy Analysis in Metastatic Hormone-Refractory Prostate Cancer
2007
·
Andrew J. Armstrong
, Elizabeth Garrett-Mayer
, et al.
·
Journal of Clinical Oncology
·
281
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
2017
·
Finn Edler von Eyben
, Giandomenico Roviello
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
197
PDF
Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate Cancer
1999
·
H. I. Scher
, W. M. K. Kelly
, et al.
·
JNCI Journal of the National Cancer Institute
·
175
Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome
1994
·
Eric J. Small
, Peter R. Carroll
·
Urology
·
175
The Influence of Statin Medications on Prostate-specific Antigen Levels
2008
·
Robert J. Hamilton
, Kenneth C. Goldberg
, et al.
·
JNCI Journal of the National Cancer Institute
·
169
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
2023
·
S. Chowdhury
, A. Bjartell
, et al.
·
Annals of Oncology
·
144
PDF
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
2009
·
Andrew J. Armstrong
, Ian F. Tannock
, et al.
·
European Journal of Cancer
·
138
Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
2015
·
S Salvi
, V Casadio
, et al.
·
British Journal of Cancer
·
134
PDF
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer
2007
·
K.N. Chi
, S.L. Ellard
, et al.
·
Annals of Oncology
·
121
PDF
Prostate-Specific Antigen Kinetics as a Measure of the Biologic Effect of Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Serologic Progression of Prostate Cancer
2002
·
Brian I. Rini
, Vivian Weinberg
, et al.
·
Journal of Clinical Oncology
·
98
Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer
1998
·
Oliver Sartor
, Maribeth Weinberger
, et al.
·
Urology
·
98
Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis
2017
·
R J S Calopedos
, V Chalasani
, et al.
·
Prostate Cancer and Prostatic Diseases
·
89
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
1995
·
William D. Figg
, Oliver Sartor
, et al.
·
The American Journal of Medicine
·
86
Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival
2001
·
Eric J. Small
, Alex McMillan
, et al.
·
Journal of Clinical Oncology
·
83
PSA Decline Is an Independent Prognostic Marker in Hormonally Treated Prostate Cancer
1999
·
Christian Palmberg
, Pasi Koivisto
, et al.
·
European Urology
·
75
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial
2017
·
Pernelle Lavaud
, Gwenaëlle Gravis
, et al.
·
European Urology
·
69
Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials
2006
·
Mark T Fleming
, Michael J Morris
, et al.
·
Nature Clinical Practice Oncology
·
68
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
2021
·
Marijo Bilusic
, Sheri McMahon
, et al.
·
Journal for ImmunoTherapy of Cancer
·
66
PDF
Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer
2011
·
Johan F. Langenhuijsen
, Dirk Badhauser
, et al.
·
Urologic Oncology Seminars and Original Investigations
·
62
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer
2020
·
Mitchell E. Gross
, David B. Agus
, et al.
·
Prostate Cancer and Prostatic Diseases
·
58
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer
2017
·
Evan Y. Yu
, Susan L. Ellard
, et al.
·
Investigational New Drugs
·
52
Long-term outcome following Thulium VapoEnucleation of the prostate
2014
·
C. Netsch
, A. Engbert
, et al.
·
World Journal of Urology
·
49
Show more works
View as search
Works count:
323
Citation count:
5,508
Year
Topic
Type